| Diabetes Mellitus
Semglee vs Humulin R U-500
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus.Deep comparison between: Semglee vs Humulin with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsHumulin has a higher rate of injection site reactions vs Semglee based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Humulin but not Semglee, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Semglee
Humulin
At A Glance
SC injection
Once daily
Long-acting insulin analog
SC injection
2-3 times daily
Human insulin
Indications
- Diabetes Mellitus
- Diabetes Mellitus
Dosing
Diabetes Mellitus, Type 1 Approximately one-third of total daily insulin requirements SC once daily at the same time each day; use concomitantly with short-acting premeal insulin.
Diabetes Mellitus, Type 2 0.2 units/kg or up to 10 units SC once daily at the same time each day for insulin-naive patients; individualize based on metabolic needs and glycemic goals.
Diabetes Mellitus SC injection 2-3 times daily approximately 30 minutes before meals; individualize dose based on metabolic needs, blood glucose monitoring results, and glycemic control goal; do not mix with other insulins or administer IV.
Contraindications
- Episodes of hypoglycemia
- Hypersensitivity to insulin glargine products or any excipient in Semglee
- Active episodes of hypoglycemia
- Hypersensitivity to HUMULIN R U-500 or any of its excipients
Adverse Reactions
Most common (>=5%) Upper respiratory tract infection, infection, accidental injury, headache
Serious Severe hypoglycemia, anaphylaxis and generalized hypersensitivity reactions, hypokalemia, peripheral edema, lipodystrophy
Postmarketing Medication errors with rapid-acting insulins administered instead of insulin glargine, localized cutaneous amyloidosis at injection site
Most common Hypoglycemia
Serious Severe allergic reactions including anaphylaxis, angioedema, bronchospasm, hypotension, shock; hypokalemia
Postmarketing Lipodystrophy, localized cutaneous amyloidosis, injection site reactions, weight gain, peripheral edema, anti-insulin antibodies
Pharmacology
Insulin glargine-yfgn is a long-acting human insulin analog that lowers blood glucose by stimulating peripheral glucose uptake in skeletal muscle and fat and inhibiting hepatic glucose production; it also inhibits lipolysis and proteolysis and enhances protein synthesis.
Human insulin; lowers blood glucose by stimulating peripheral glucose uptake in skeletal muscle and fat and inhibiting hepatic glucose production, and also inhibits lipolysis and proteolysis while enhancing protein synthesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Semglee
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (3/12) · Qty limit (6/12)
Humulin
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (0/12)
UnitedHealthcare
Semglee
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (0/8)
Humulin
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Semglee
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Humulin
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Semglee.
No savings programs available for Humulin.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SemgleeView full Semglee profile
HumulinView full Humulin profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.